Literature DB >> 8112320

Differential secretion of alpha 1-acid glycoprotein occurs in the Golgi complex of isolated rat hepatocytes. Evidence of partial retention in the Golgi.

C Poüs1, J Guibourdenche, A Drechou, G Durand.   

Abstract

Using weakly basic amines, we investigated the step at which the secretion kinetics of concanavalin-A-retained and nonretained alpha 1-acid glycoprotein glycoforms diverge in isolated rat hepatocytes. Both chloroquine and primaquine, whose action on protein secretion is targeted to terminal domains of the Golgi apparatus, cancelled the kinetic difference without influencing carbohydrate chain sialylation. To test for a possible interaction of alpha 1-acid glycoprotein with Golgi membranes, we also permeabilized control and primaquine-treated hepatocytes, as well as purified Golgi preparations, with saponin. In each case, we found that alpha 1-acid glycoprotein was associated with Golgi membranes, the association being more marked in primaquine-treated cells than in control cells. Membrane-bound alpha 1-acid glycoprotein appeared to be preferentially retained on concanavalin A. Such retention could account for the divergent secretion kinetics of alpha 1-acid glycoprotein glycoforms.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8112320     DOI: 10.1111/j.1432-1033.1994.tb18590.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  2 in total

Review 1.  Alpha 1-acid glycoprotein (orosomucoid): pathophysiological changes in glycosylation in relation to its function.

Authors:  W van Dijk; E C Havenaar; E C Brinkman-van der Linden
Journal:  Glycoconj J       Date:  1995-06       Impact factor: 2.916

2.  Pompe disease results in a Golgi-based glycosylation deficit in human induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Kunil K Raval; Ran Tao; Brent E White; Willem J De Lange; Chad H Koonce; Junying Yu; Priya S Kishnani; James A Thomson; Deane F Mosher; John C Ralphe; Timothy J Kamp
Journal:  J Biol Chem       Date:  2014-12-08       Impact factor: 5.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.